Investor's Business Daily • yesterday
Biogen stock underplayed promising Alzheimer's Disease drug results on investor concern over a patient seizure.
Investor's Business Daily • 3 days ago
European, Japanese or specialty pharma could look to acquire Ariad as it rapidly closes in on approval of a lung cancer drug, RBC says.
MarketWatch • 4 days agoRoche Group's Genentech says Avastin with chemo has been approved for specific advanced ovarian cancer treatment
Roche Group's Genentech said Tuesday that its Avastin drug had been approved by the Food and Drug Administration to treat a specific type of advanced ovarian cancer in combination with chemotherapy. The ...
Forbes • 4 days ago
The year 2016 was a mixed one for Swiss pharmaceutical giant Roche . While the overall business improved on the back of the launch of new products and growth in the HER2+ drug franchise, the stock fell as investors remained cautious regarding broader industry factors. Overall, there was no change
Bloomberg • 5 days ago
Jean-Paul and Martine Clozel represent the dream of just about every pharmaceutical researcher. After the multinational that employed them declined to pursue a compound they discovered, the Clozels founded ...
Zacks • 5 days ago
Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.
Reuters • 5 days ago
Roche's Gazyva cancer drug did not show a significant overall survival benefit and raised greater safety concerns than its predecessor Rituxan, a study showed, raising doubts over the Swiss pharmaceuticals group's bid to replace a key blockbuster. Gazyva is used with the chemotherapy drug bendamustine to treat follicular lymphoma (FL) and Roche is counting on it to help mitigate the impact of biosimilars on Rituxan, whose patents expired this year.. Roche failed to find a follow-up drug to its Avastin blockbuster this year and faces competition from rivals including Novartis whose Sandoz generics unit is hot on Rituxan's heels.
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||27.59 - 27.94|
|52 Week Range||25.25 - 35.13|
|PE Ratio (TTM)||21.50|
|Dividend & Yield||1.02 (3.67%)|
|1y Target Est||34.65|